CN112494598B - Effective part composition for treating pharyngitis and application thereof - Google Patents
Effective part composition for treating pharyngitis and application thereof Download PDFInfo
- Publication number
- CN112494598B CN112494598B CN202011543847.6A CN202011543847A CN112494598B CN 112494598 B CN112494598 B CN 112494598B CN 202011543847 A CN202011543847 A CN 202011543847A CN 112494598 B CN112494598 B CN 112494598B
- Authority
- CN
- China
- Prior art keywords
- total
- extract
- parts
- traditional chinese
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 65
- 239000003814 drug Substances 0.000 claims abstract description 55
- 229930182490 saponin Natural products 0.000 claims abstract description 36
- 150000007949 saponins Chemical class 0.000 claims abstract description 36
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 32
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 30
- 229930003944 flavone Natural products 0.000 claims abstract description 30
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 30
- 235000011949 flavones Nutrition 0.000 claims abstract description 30
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 14
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 14
- 241001465382 Physalis alkekengi Species 0.000 claims abstract description 14
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 13
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 235000017709 saponins Nutrition 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 229930003935 flavonoid Natural products 0.000 claims description 5
- 150000002215 flavonoids Chemical class 0.000 claims description 5
- 235000017173 flavonoids Nutrition 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 18
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 28
- 239000002775 capsule Substances 0.000 description 22
- 241000700159 Rattus Species 0.000 description 15
- 210000003800 pharynx Anatomy 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 240000001624 Espostoa lanata Species 0.000 description 7
- 235000009161 Espostoa lanata Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- -1 vaseline Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 150000001875 compounds Chemical group 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010065716 Pharyngeal inflammation Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960001931 ampicillin sodium Drugs 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 241000722953 Akebia Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001448424 Ophiopogon Species 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 235000013548 tempeh Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine effective part composition for treating pharyngitis, which comprises a total flavone extract and a total saponin extract; the total flavone extract is extracted from wild chrysanthemum, tangerine pith and physalis alkekengi, and the total saponin extract is extracted from ophiopogon japonicus. The composition comprises 2-8 parts of total flavone extract and 2-10 parts of total saponin extract according to parts by weight. Experiments prove that the effective part composition has a remarkable synergistic effect in the aspect of treating pharyngitis. The product has definite components, stable curative effect, small dosage and high safety, not only accords with the formula principle of the traditional Chinese medicine for treating the chronic pharyngitis, but also accords with the development requirement of the modernization of the traditional Chinese medicine, and has important significance for promoting the transformation of imitation of the medicine industry to independent innovation and the internationalization of the traditional Chinese medicine in China.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to an effective part composition for treating pharyngitis and application thereof.
Background
Chronic pharyngitis is a chronic inflammation of the pharyngeal mucosa, submucosa and lymphoid tissues. Diffuse pharyngeal inflammation is often part of chronic inflammation of the upper respiratory tract; localized pharyngeal inflammation is usually inflammation of pharyngeal lymphoid tissue. The disease is common in clinic, the course of disease is long, and the symptoms are easy to recur. Chronic pharyngitis is common in adults and also in children. The general symptoms are not obvious, and the local symptoms are the main symptoms. The symptoms of various types of chronic pharyngitis are similar and various, such as pharyngeal discomfort, foreign body sensation, pharyngeal secretion difficult to be expelled, pharyngeal itching, burning sensation, dryness or irritation, and slight pain. The back wall of pharynx usually causes the adhesion of relatively viscous secretions due to chronic inflammation of the pharynx, and the mouth-opening breath at night due to lesions of the nose, sinuses and nasopharynx, which often causes irritable cough and nausea in the morning. Frequent swallowing can be manifested by a foreign body sensation in the pharynx. The patients with little pharyngeal secretion and difficult cough are usually manifested as habitual dry cough and phlegm-clearing action of throat, and bleeding of pharyngeal mucosa can be caused if cough is done forcefully or throat-clearing action is done forcefully, resulting in blood in the secretion.
According to the clinical sign examination of western medicine, the posterior pharyngeal wall or the tongue root lymph follicles are hyperplastic, and in severe cases, there is an attachment of the compound, which indicates that there is a foreign body sensation in the throat, but the food intake is normal. The diagnosis is based on that no space occupying lesion is found in the examination of the pharynx or the larynx, the local part has lymphofollicular hyperplasia, even the compound is attached, and the esophagus is examined normally. At present, the western medicines on the market, namely the throat tablet, mainly comprise a Huasu tablet and a mingzhijiekamine buccal tablet, and the two tablets do not contain antibiotics. The main component of the Huasu tablet is cydiodine, iodine molecules have super strong sterilization and anti-infection effects, and can rapidly kill various pathogenic microorganisms including bacterial propagules, fungi, spores and viruses at oral cavity and throat parts. The unique buccal anti-inflammatory mode of the Huasu tablet directly acts on the infected part of diseases, and the cool mint moistens the throat, so that the throat diseases can be effectively treated, but adverse reactions such as mental depression, nervousness and the like can be generated by taking iodine and iodine compounds for a long time. In addition, the main component of the mingzhijiolamin buccal tablet is dequalinolamin which can kill bacteria by destroying the surfaces of bacteria. The western medicine has quick response and obvious effect in a short treatment period, but has certain influence on the body, and can cause some side effects after being taken by part of people; the western medicine aims at symptomatic treatment of diseases, has obvious effect of eliminating symptoms, aims at the characteristics of symptoms, and is easy to relapse when treating chronic pharyngitis.
The traditional Chinese medicine considers that the chronic pharyngitis is related to emotional depression and qi activity disorder. Like the plum core located in the throat, the cough cannot emerge and the throat cannot descend, so it is called "plum-stone qi". This disease is usually caused by lung-kidney yin deficiency or repeated attack of wind-heat and throat impediment, retention of the remaining pathogenic factors, impairment of body fluids and fluid consumption, impairment of yin fluid and loss of nourishment of throat, and deficient fire in combination. This disease usually occurs on the basis of deficiency of yin, yang, qi and blood of the zang-fu organs, and generally has a long course of disease. Clinically, yin deficiency is usually considered as excessive, yang deficiency is relatively rare, and there are also symptoms of excess in deficiency with phlegm accumulation or blood stasis on the basis of yin deficiency or yang deficiency, which should be carefully distinguished during differentiation. Chronic pharyngitis is mostly due to deficiency syndrome, and the major therapy is mainly tonifying, or nourishing yin to reduce pathogenic fire, or warming and tonifying spleen and kidney, leading to the origin. Because the course of disease is long and quick-acting is difficult to take, long-term administration of the medicine can nourish yin and prevent it from becoming greasy, and warm tonification should prevent it from becoming dry. For phlegm with blood stasis, it is not suitable to counteract and impair the healthy qi because of its deficiency with excess, so the pathogenic condition is more lingering. Besides the medication, it is also very important to properly dredge the mind and regulate qi.
However, the traditional Chinese medicine decoction pieces are not easily accepted by patients due to low content of effective components, large dosage, inconvenience and bitter taste of the medicines, but the content of the effective components is improved, the dosage is reduced, the taking is convenient, good medicines are not bitter, and the accepted population is increased.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the effective part composition for treating pharyngitis, which has obvious curative effect on the treatment of the pharyngitis and can be applied to various preparations.
The specific technical scheme is as follows:
the invention aims to provide a traditional Chinese medicine effective part composition for treating pharyngitis, which is characterized by comprising a total flavone extract and a total saponin extract;
the total flavone extract is extracted from wild chrysanthemum, tangerine pith and Physalis alkekengi (Physicalis Peruviana L.), and the total saponin extract is extracted from ophiopogon japonicus.
The Physalis alkekengi is a dried product of a fruit of a solanaceae plant, namely, a berry (Physicalis peruviana L.).
Experiments prove that the traditional Chinese medicine effective part composition has a remarkable synergistic effect and a remarkable curative effect on pharyngitis.
Further, the traditional Chinese medicine effective part composition comprises 2-8 parts of total flavone extract and 2-10 parts of total saponin extract in parts by weight.
Furthermore, the traditional Chinese medicine effective part composition comprises 6 parts by weight of total flavone extract and 5 parts by weight of total saponin extract.
Further, the content of total flavonoids in the total flavonoid extract is not less than 50wt%, and the content of total saponins in the total saponin extract is not less than 50 wt%.
Further, the preparation method of the traditional Chinese medicine effective part composition comprises the following steps:
(1) preparing a total flavone extract: taking wild chrysanthemum, tangerine pith and physalis alkekengi as raw materials, adding 80-95% ethanol in an amount which is 15-30 times of the total weight of the raw materials, performing reflux extraction at 70-80 ℃ for 1-3 times for 2 hours each time, filtering, combining filtrates, recovering ethanol under reduced pressure, adding water to dilute concentrated solution, passing through a macroporous resin column at a flow rate of 0.8-1 mL/min, eluting with deionized water in an amount which is 6-10 times of the volume of the column, eluting with 70% ethanol in an amount which is 8-15 times of the volume of the column, collecting eluate, recovering ethanol under reduced pressure, concentrating, and drying to obtain a total flavone extract;
(2) preparing a total saponin extract: taking ophiopogon japonicus as a raw material, adding 75-85% ethanol which is 8-10 times of the weight of ophiopogon japonicus, carrying out reflux extraction at 75-80 ℃ for 1-1.5 h, filtering to obtain filtrate, repeatedly extracting filter residues once, combining two filtrates, recovering ethanol under reduced pressure until the relative density is 1: 1-1: 2, adding water saturated n-butyl alcohol for extraction for three times, combining n-butyl alcohol parts, recovering n-butyl alcohol until each mL of the n-butyl alcohol contains 1-1.5 g of crude drugs, passing through a macroporous resin column at the flow rate of 0.8-1 mL/min, eluting with distilled water which is 4-5 times of the column volume, eluting with 70% ethanol which is 4-5 times of the column volume, collecting eluate, recovering under reduced pressure, and drying to obtain the total saponin extract.
And further, in the step (1), the mass ratio of the wild chrysanthemum flower to the tangerine pith to the physalis alkekengi is 1: (1-3): (1-4), most preferably 1: 2: 3.
and (2) further, the macroporous resin column used in the step (1) is an HPD-100 macroporous resin column, and the macroporous resin column used in the step (2) is a D101 macroporous resin column.
The percentage of ethanol in the invention is volume percentage.
The invention also aims to provide the application of the traditional Chinese medicine effective part composition in preparing the medicine for treating pharyngitis.
The extracts of the two effective parts are taken according to the weight ratio of the effective parts, and are prepared into pharmaceutically acceptable dosage forms, such as tablets, granules, hard capsules, pills, dripping pills, soft capsules and the like without adding auxiliary materials or adding pharmaceutically conventional auxiliary materials.
The above-mentioned pharmaceutically conventional excipients include, but are not limited to, binders such as cellulose derivatives, alginates, gelatin and polyvinylpyrrolidone; diluents, starch, sugar powder, dextrin, lactose, microcrystalline cellulose, mannitol; lubricants, such as talc, magnesium stearate, aerosil and polyethylene glycol; disintegrants, such as carboxymethyl starch sodium, low-substituted hypromellose, croscarmellose; absorption promoters, such as quaternary ammonium compounds; surfactants such as cetyl alcohol, sodium lauryl sulfate; excipients, such as lactose, starch, sucrose, dextrin, calcium carbonate, aluminum sulfate, magnesium oxide, magnesium stearate, sodium bicarbonate, glycerol, propylene glycol, polyethylene glycol, sorbitol, lanolin, vaseline, microcrystalline cellulose, beeswax, wood wax, liquid paraffin, resin, higher wax, pressure sensitive adhesive, semisynthetic fatty acid ester, etc.
The invention has the following beneficial effects:
the traditional Chinese medicine composition takes the traditional Chinese medicine theory as a guiding idea, and is combined with related research results at home and abroad, so that the traditional Chinese medicine composition has an obvious effect on treating chronic gastritis. The wild chrysanthemum flower is used as a monarch drug in the formula, is bitter, pungent and cool in taste, has the effects of clearing heat and removing toxicity, dispelling wind and heat, dissipating blood stasis, improving eyesight and reducing blood pressure, and is used for treating pharyngitis, pneumonia, diphtheria, gastroenteritis, furuncle, carbuncle and other symptoms, so the wild chrysanthemum flower is a monarch drug. The physalis alkekengi is a ministerial drug, has the effects of clearing heat, detoxifying and promoting urination, and is used for treating heat cough, pharyngalgia, dysentery, edema, furuncle and erysipelas. The combination of physalis alkekengi and wild chrysanthemum has the efficacy of clearing heat, reducing pathogenic fire and reading, so the physalis alkekengi is a ministerial drug. The ophiopogon root is an adjuvant drug and has the effects of nourishing yin and moistening lung; benefiting stomach and promoting fluid production; it has the actions of clearing heart fire and relieving restlessness, and is used as adjuvant drug for dry cough due to lung dryness, pulmonary abscess, cough due to yin deficiency, thirst due to body fluid consumption, throat pain, constipation due to intestinal dryness, etc. Tangerine channel is a guiding drug, and Tangerine channel is bitter and sweet in flavor and neutral in nature. Spleen and lung meridians. Dredge collaterals, resolve phlegm and stop cough. Can be used for treating cough with excessive phlegm and chest and hypochondrium pain. Huang Qi is a guiding drug because it is neutral in nature and can harmonize the other drugs and direct them to the disease. The medicines in the formula supplement each other, but lack one, and the formula is reasonable according to the monarch, minister, assistant and guide theory of the traditional Chinese medicine, so that the effects of clearing heat and removing toxicity, dispelling wind and clearing heat, clearing heart fire and relieving restlessness, nourishing yin and lowering fire, moistening dryness and relieving sore throat are achieved together.
Experiments prove that the effective part composition has a remarkable synergistic effect in the aspect of treating pharyngitis.
The product has definite components, stable curative effect, small dosage and high safety, not only accords with the formula principle of the traditional Chinese medicine for treating the chronic pharyngitis, but also accords with the development requirement of the modernization of the traditional Chinese medicine, and has important significance for promoting the transformation of imitation of the medicine industry to independent innovation and the internationalization of the traditional Chinese medicine in China. After examining the relevant documents and patents, the reports that the effective parts of the wild chrysanthemum flower, the tangerine pith, the ophiopogon japonicus and the physalis alkekengi are taken as raw materials, produced, processed and prepared into a suitable pharmaceutical preparation for treating or assisting in treating the chronic pharyngitis are not found.
Detailed Description
The principles and features of this invention are described below in conjunction with examples, which are set forth to illustrate, but are not to be construed to limit the scope of the invention. The dosage in the actual production is not limited to the dosage of the drugs in the examples, and the dosage can be measured in units of ton, kilogram, gram and the like, but the dosage proportion of the raw materials is still according to the technical scheme of the invention.
In a specific embodiment, the method for measuring the content of the total flavonoids comprises the following steps: precisely weighing rutin control substance dried at 120 deg.C under reduced pressure to constant weight of about 10mg, placing in 100mL volumetric flask, adding 70% ethanol 70mL, placing in water bath, slightly heating for dissolving, cooling, adding 70% ethanol to scale, and shaking. Precisely sucking 1.0 mL, 2.0 mL, 3.0 mL, 4.0 mL and 5.0mL of reference substance solution, respectively placing in a 10mL measuring flask, respectively adding water 4.0, 3.0, 2.0, 1.0 and 0, adding 5% sodium nitrite solution 0.3mL, shaking up, standing for 6min, adding 10% aluminum nitrate solution 0.3mL, shaking up, standing for 6min, adding 4% sodium hydroxide 4mL, adding water scale, shaking up, and standing for 12 min; preparing blank solution by the same method. Absorbance was measured at 510 nm. And drawing a standard curve by taking the absorbance as the ordinate and the concentration as the abscissa. 100mg of the sample is taken and put into a 100ml volumetric flask, 70 percent ethanol is added to the scale, and the mixture is shaken and filtered. Precisely measuring 3mL of filtrate, adding 2mL of water, adding 0.3mL of 5% sodium nitrite solution, shaking uniformly, standing for 6min, adding 0.3mL of 10% aluminum nitrate solution, shaking uniformly, standing for 6min, adding 4mL of 4% sodium hydroxide, adding water scale, shaking uniformly, and standing for 12 min. Absorbance was measured at 510nm and the content was calculated according to the standard curve equation.
In a specific embodiment, the method for measuring the content of the total saponins comprises the following steps: precisely weighing 5.00mg of oleanolic acid reference substance, adding methanol to dissolve to constant volume of 25mL, and making into 0.2mg per mL of oleanolic acid reference substance. Precisely transferring 0, 0.1,0.2,0.3,0.4,0.5 and 0.6mL of a reference substance solution into 7 dry test tubes with plugs respectively, volatilizing the solvent in a water bath, adding 0.2mL of a freshly prepared 50mL/L vanillin glacial acetic acid solution and 0.8mL of perchloric acid respectively, heating in a constant-temperature water bath at 60 ℃ for 15min, taking out, cooling for 2min with running water, adding 5mL of glacial acetic acid, shaking up, blanking with a follow-up reagent, performing a spectrophotometry test, and measuring the absorbance at the wavelength of 544 nm. And drawing a standard curve by taking the absorbance as the ordinate and the oleanolic acid amount as the abscissa. Taking the effective part of the akebia stem and astragalus total saponin to be 10mg, adding methanol for dissolving and fixing the volume to be 10 mL. Taking 0.5mL of sample solution, placing the sample solution in a dry test tube with a plug, volatilizing the solvent in a water bath, adding 0.2mL of a freshly prepared 50mL/L vanillin glacial acetic acid solution and 0.8mL of perchloric acid, heating in a constant-temperature water bath at 60 ℃ for 15min, taking out, cooling for 2min with running water, adding 5mL of glacial acetic acid, shaking up, measuring the absorbance, substituting into a standard curve, and calculating to obtain the test solution.
Example 1
The capsule for treating pharyngitis is prepared by the following formula: 120g of total flavone extract and 100g of total saponin extract.
The preparation method of the total flavone extract comprises the following steps: taking 1 part of wild chrysanthemum flower, 2 parts of tangerine pith and 3 parts of physalis alkekengi in parts by weight as raw materials, adding 90% ethanol which is 20 times of the weight of the raw materials, carrying out reflux extraction for 3 times at 75 ℃ for 2 hours each time, filtering, combining the filtrates, recovering ethanol under reduced pressure, adding water to dilute the concentrated solution to the volume of the original filtrate, passing the concentrated solution through an HPD-100 macroporous resin column at the flow rate of 1mL/min, eluting with deionized water which is 8 times of the volume of the column, eluting with 70% ethanol which is 10 times of the volume of the column, collecting the eluate, recovering ethanol under reduced pressure, concentrating, and drying to obtain a total flavone extract, wherein the total flavone content is measured to be 52.3%.
Preparing a total saponin extract: taking ophiopogon japonicus as a raw material, adding 80% ethanol which is 10 times of the weight of the ophiopogon japonicus, performing reflux extraction at 80 ℃ for 1.5h, filtering to obtain filtrate, performing repeated operation extraction on filter residues once, combining two filtrates, recovering ethanol under reduced pressure until the relative density is 1:1.5, adding equal mass of water saturated n-butanol, performing extraction for three times, combining n-butanol parts, recovering n-butanol until each mL contains 1-1.5 g of crude drug, passing through D101 macroporous resin at the flow rate of 1mL/min, eluting with 5 times of column volume of distilled water, eluting with 5 times of column volume of 70% ethanol, collecting eluate, recovering under reduced pressure, and drying to obtain a total saponin extract, wherein the total saponin content is 56.1%.
The preparation method comprises the following steps: taking the above effective components according to the prescription, pulverizing, mixing, adding starch to 300g, mixing, granulating, and making into No. 1 capsule with content of 0.3g per capsule.
Example 2
The tablet for treating pharyngitis is prepared by the following formula: 120g of total flavone extract and 100g of total saponin extract.
The preparation method of the total flavone extract and the total saponin extract is the same as that of example 1.
The preparation method comprises the following steps: taking the above effective part extracts according to the prescription, pulverizing, mixing, adding hydroxypropyl methylcellulose 40g, microcrystalline cellulose 20g, silica gel micropowder 5g, adding lactose to 300g, mixing, granulating, and tabletting.
Example 3
The soft capsule for treating pharyngitis is prepared by the following formula: 140g of total flavone extract and 100g of total saponin extract.
The preparation method of the total flavone extract and the total saponin extract is the same as that of example 1.
The preparation method comprises the following steps: taking the above effective components according to the prescription, adding polyethylene glycol 400 to total amount of 300g, mixing, and making into soft capsule.
Example 4
The preparation of the granules for treating pharyngitis comprises the following components: 240g of total flavone extract and 200g of total saponin extract.
The preparation method of flavone extract and total saponin extract is the same as that of example 1.
The preparation method comprises the following steps: and (3) taking the extracts of the effective parts according to a prescription, adding 10% of starch and 90% of ethanol, and granulating to obtain the traditional Chinese medicine.
Example 5
The preparation of the granules for treating pharyngitis comprises the following components: 3kg of total flavone extract and 2kg of total saponin extract.
The preparation method of flavone extract and total saponin extract is the same as that of example 1.
The preparation method comprises the following steps: taking the above effective components according to the prescription, adding 10% starch and 90% ethanol, granulating, and packaging 5g of the obtained granule per bag.
140 patients with pharyngitis were treated with the granules prepared in example 5. The treatment scheme comprises the following steps: it is administered orally 1 bag at a time, 2 times daily, and 8 weeks as a treatment course. As a result: 78 cases are cured, 41 cases are improved, 13 cases are obviously effective, 8 cases are ineffective, and the total effective rate is 94.3 percent.
Comparative example 1
Taking 100g of ophiopogon japonicus, 60g of physalis alkekengi, 40g of tangerine pith and 20g of wild chrysanthemum flower, adding 10 times of water by mass, decocting for 2h, filtering, adding 8 times of water into medicine residues, decocting for 1.5h, filtering, combining filtrates, concentrating under reduced pressure, drying under reduced pressure, crushing, adding starch to 300g, filling into No. 1 capsules, and preparing into capsules, wherein the content of each capsule is 0.3 g.
Comparative example 2
Taking 20g of the total flavone extract prepared in the example 1 and 200g of the total saponin extract prepared in the example 1, adding starch to 300g, filling into No. 1 capsules, and preparing into capsules, wherein the content of each capsule is 0.3 g.
Comparative example 3
220g of the total flavone extract prepared in the example 1 is taken, starch is added to 300g, and the mixture is filled into a No. 1 capsule, wherein the content of each capsule is 0.3g, and the capsule is prepared.
Comparative example 4
220g of the total saponin extract prepared in the example 1 is taken, starch is added to 300g, and the mixture is filled into a No. 1 capsule, wherein the content of each capsule is 0.3g, and the capsule is prepared.
Comparative example 5
The capsule for treating pharyngitis is prepared by the following formula: 120g of total flavone extract and 100g of total saponin extract.
The difference from the example 1 is that the total flavone extract of the comparative example 5 is extracted from the mixture of wild chrysanthemum and tangerine pith with the mass ratio of 1:2, and the extraction method is the same as the example 1; the total saponin extract was the same as in example 1.
220g of the above prescription medicines are added with starch to 300g, and the mixture is filled into No. 1 capsules, and the content of each capsule is 0.3g, so that capsules are prepared.
Experiment of
In order to further verify the pharmacological effects of the invention, animal pharmacodynamic experiments are carried out by using the capsules of the invention.
The influence of the compound on the pharyngitis of the rats is verified.
1 reagents, samples and animals
1.1 reagents
Chemical reagent III works of xylene, Tianjin; ether (analytically pure), tempeh chemical reagent three factories; 0.9% chlorinated physiological saline, Feng boat chemical reagent science and technology Limited, Tianjin; carrageenan, SIDMA, sodium carboxymethylcellulose, beijing feng li essence trader trade llc; ampicillin sodium for injection, Shandong Lu anti-medicine, Inc.
1.2 test samples
The capsules obtained in example 1 and comparative examples 1 to 5 were used as the subjects.
Example 1 is labeled as sample 1, and comparative examples 1 to 5 are labeled as samples 2 to 6 in sequence.
Control group: manyanshu lemon pharyngitis tablet, national Standard Z61020304 Xian Keli pharmacy Co., Ltd
Before administration, the corresponding preparation is taken, capsule content and the Manyanshu lemon pharyngitis tablet are taken, ground, prepared into solution with required drug concentration of 2.6g/ml by adopting pure water, and the administration dosage of the mouse is calculated according to a conversion formula of the body surface area of the administration dosage of the mouse to the gavage of 39.05 g.kg-1·d-1The administration dose of the rat is 48.28 g.kg-1·d-1。
1.3 Experimental animals
Kunming mouse (20 + -2) g, female and male half, SPF grade, provided by Shandong university of traditional Chinese medicine laboratory animal center.
SD rats (200 + -20) g, half male and half female, were provided by the Experimental animals center of Shandong university of traditional Chinese medicine.
2 method of experiment
2.1 xylene-induced ear swelling experiments in mice
2.1.1 animal groups: 80 mice, each half of male and female, were randomly divided into 8 groups of 10 mice each, i.e., blank group, control group, sample 1 group, sample 2 group, sample 3 group, sample 4 group, sample 5 group, and sample 6 group. The administration is carried out once daily for 3 days.
2.1.2 Experimental methods: 1h after the last dose, mice were coated with 50 ul/mouse of xylene reagent in the right ear and not coated with a self-blank in the left ear. After coating xylene for 30min, the mice were sacrificed by removing the cervical vertebrae, and the corresponding round ear pieces of the left and right ears were punched out by a punch with an inner diameter of 8 mm. Weighing on a tunzi balance, taking the difference of the mass of the right ear piece minus the mass of the left ear piece as swelling degree, comparing the swelling degree of each group, and calculating the swelling inhibition ratio: the swelling inhibition rate is (negative control swelling degree-drug group swelling degree)/negative control swelling degree. The results are shown in Table 1.
TABLE 1 Effect of Paralyne on the degree of swelling of mouse auricles
2.2 rat granuloma proliferation test due to Cotton balls
2.2.1 animal groups: SD rats are randomly divided into 8 groups, and each group comprises 10 rats, namely a blank group, a control group, a sample 1 group, a sample 2 group, a sample 3 group, a sample 4 group, a sample 5 group and a sample 6 group. The administration is carried out once a day for 10 days.
2.2.2 Experimental methods: SD rats were subjected to small abdominal incisions under ether light anesthesia and sterile conditions, the subcutaneous tissues of the rats were expanded with vascular forceps and tweezers, and 1 each of 30. + -.1 mg sterilized cotton balls was subcutaneously implanted in the bilateral groin, followed by suturing. Before use, the cotton balls are added with 1mg/0.1mL of ampicillin sodium and baked in an oven at 60 ℃ to prevent infection. Except for the blank control group (normal saline), the other administration groups started intragastric administration on the day of surgery, 1 time/day, and 10 days continuously. The rats are killed by bleeding femoral artery after administration for 1h on the 10 th day, the granulation tissue of the cotton ball is stripped and taken out, the excess fat which is cut off in the week is removed, the cotton ball is taken out after drying for 5h in a 70 ℃ oven, weighing is carried out, the weight of the cotton ball is subtracted from the weighed mass to obtain the mass of the granuloma, and the granulation inhibition rate is calculated. The granulation inhibition rate is (blank control granulation quality-treatment granulation quality)/blank granulation quality. The results are shown in Table 2.
TABLE 2 Effect on the rat Cotton boll granuloma formation experiment
2.3 Carrageenan-induced swelling of rat feet
2.3.1 animal groups: SD rats are randomly divided into 8 groups, and each group comprises 10 rats, namely a blank group, a control group, a sample 1 group, a sample 2 group, a sample 3 group, a sample 4 group, a sample 5 group and a sample 6 group. The administration is carried out once a day for 5 days.
2.3.2 Experimental methods: after 30min of the last administration, 0.1mL of 1% carrageenan is subcutaneously injected into the plantar region of the right hind foot of each mouse per mouse to cause inflammation, so that the ankle joint circumference is measured at different time points before and after causing inflammation, and is measured once every hour for four times, and the swelling degree (the circumference of the ankle joint after causing inflammation-the circumference of the ankle joint before causing inflammation) is calculated. The results are shown in Table 3.
TABLE 3 Effect on carrageenan-induced group swelling
2.4 experiment of mice peritoneal cavity leukocyte migration caused by sodium carboxymethylcellulose
2.4.1 animal groups: 80 mice, each half of male and female, were randomly divided into 8 groups of 10 mice each, i.e., blank group, control group, sample 1 group, sample 2 group, sample 3 group, sample 4 group, sample 5 group, and sample 6 group. The administration is carried out once daily for 3 days.
2.4.2 test methods: after 30min of the last administration, the mice in each group except the control group were injected with 0.5ml of 1% sodium carboxymethylcellulose in the abdominal cavity, the animals were sacrificed after 30min, each mouse was injected with 5ml of 0.9% physiological saline in the abdominal cavity, the abdomen was gently kneaded, the abdominal cavity was dropped on a cell plate, and the white blood cells were counted under a conventional light microscope. The results are shown in Table 4.
TABLE 4 Effect on experiments on migration of leukocytes from mouse peritoneal cavity caused by sodium carboxymethylcellulose
Through the xylene-induced mouse ear swelling experiment, the cotton ball-induced rat granuloma proliferation experiment, the carrageenan-induced rat foot swelling experiment and the sodium carboxymethylcellulose-induced mouse abdominal cavity leukocyte migration experiment, the sample 1 group is far superior to other sample groups in the aspects of inhibiting swelling and granuloma proliferation and relieving foot swelling and leukocyte migration experiments, and the selected effective part composition has obvious effect and generates obvious synergistic effect.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (4)
1. A Chinese medicinal effective part composition for treating pharyngitis is characterized by comprising a total flavone extract and a total saponin extract;
the total flavone extract is extracted from wild chrysanthemum, tangerine pith and physalis alkekengi, and the total saponin extract is extracted from ophiopogon japonicus;
the traditional Chinese medicine composition comprises 6 parts of total flavone extract and 5 parts of total saponin extract according to parts by weight;
the preparation method comprises the following steps:
(1) preparing a total flavone extract: taking wild chrysanthemum, tangerine pith and physalis alkekengi as raw materials, adding 80-95% ethanol in an amount which is 15-30 times the weight of the raw materials, performing reflux extraction for 1-3 times at 70-80 ℃ for 2 hours each time, filtering, combining filtrates, recovering ethanol under reduced pressure, adding water to dilute concentrated solution, passing through a macroporous resin column at a flow rate of 0.8-1 mL/min, eluting with deionized water in an amount which is 6-10 times the volume of the column, eluting with 70% ethanol in an amount which is 8-15 times the volume of the column, collecting eluate, recovering ethanol under reduced pressure, concentrating, and drying to obtain a total flavone extract;
(2) preparing a total saponin extract: taking ophiopogon japonicus as a raw material, adding 75-85% ethanol which is 8-10 times of the weight of ophiopogon japonicus, carrying out reflux extraction at 75-80 ℃ for 1-1.5 h, filtering to obtain filtrate, repeatedly extracting filter residues once, combining two filtrates, recovering ethanol under reduced pressure until the relative density is 1: 1-1: 2, adding water saturated n-butanol, extracting for three times, combining n-butanol parts, recovering n-butanol until each mL contains 1-1.5 g of crude drug, passing through a macroporous resin column at the flow rate of 0.8-1 mL/min, eluting with distilled water which is 4-5 times of the column volume, eluting with 70% ethanol which is 4-5 times of the column volume, collecting eluate, recovering under reduced pressure, and drying to obtain a total saponin extract;
in the step (1), the mass ratio of the wild chrysanthemum flower to the tangerine pith to the physalis alkekengi is 1: 2: 3.
2. the composition of the effective traditional Chinese medicine parts as claimed in claim 1, wherein the content of total flavonoids in the total flavonoids extract is not less than 50wt%, and the content of total saponins in the total saponins extract is not less than 50 wt%.
3. Use of the composition of the effective fraction of Chinese traditional medicine as claimed in claim 1 or 2 in preparing medicine for treating pharyngitis.
4. The use of claim 3, wherein the composition of the effective parts of the Chinese traditional medicine is used as an effective component to prepare tablets, granules, hard capsules, pills or soft capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011543847.6A CN112494598B (en) | 2020-12-23 | 2020-12-23 | Effective part composition for treating pharyngitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011543847.6A CN112494598B (en) | 2020-12-23 | 2020-12-23 | Effective part composition for treating pharyngitis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112494598A CN112494598A (en) | 2021-03-16 |
| CN112494598B true CN112494598B (en) | 2022-04-12 |
Family
ID=74923304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011543847.6A Active CN112494598B (en) | 2020-12-23 | 2020-12-23 | Effective part composition for treating pharyngitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112494598B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118020937B (en) * | 2024-03-28 | 2024-09-10 | 广州市东鹏食品饮料有限公司 | Beverage capable of clearing and nourishing throat and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686152A (en) * | 2005-05-13 | 2005-10-26 | 张海峰 | Traditional Chinese medicinal preparation for treating chronic bronchitis, its preparation method and application |
| CN102558284A (en) * | 2010-12-24 | 2012-07-11 | 苏州宝泽堂医药科技有限公司 | Method for extracting ophiopogonin D |
| CN104013795A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Granule used for swollen sore throats |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284573C (en) * | 2004-09-14 | 2006-11-15 | 马耀茹 | Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis |
-
2020
- 2020-12-23 CN CN202011543847.6A patent/CN112494598B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686152A (en) * | 2005-05-13 | 2005-10-26 | 张海峰 | Traditional Chinese medicinal preparation for treating chronic bronchitis, its preparation method and application |
| CN102558284A (en) * | 2010-12-24 | 2012-07-11 | 苏州宝泽堂医药科技有限公司 | Method for extracting ophiopogonin D |
| CN104013795A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Granule used for swollen sore throats |
Non-Patent Citations (3)
| Title |
|---|
| 大孔吸附树脂纯化麦冬总皂苷的工艺研究;周跃华等;《中草药》;20031225;第34卷(第12期);第2.1、2.8节 * |
| 野菊花总黄酮的提取与纯化;罗显华等;《食品科技》;20080720(第07期);第179页第1段，摘要 * |
| 锦灯笼宿萼中总黄酮的提取、富集及含量测定;杨异卉等;《哈尔滨医科大学学报》;20121225;第46卷(第06期);第554页左栏第1段，第553页摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112494598A (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| US10105408B2 (en) | Traditional Chinese medicine composition and preparation method and use thereof | |
| CN104887952B (en) | A composition with the effect of nourishing yin and moistening the lung and its preparation method and application | |
| CN112494598B (en) | Effective part composition for treating pharyngitis and application thereof | |
| CN104324125B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CN106729140B (en) | Compound preparation for treating influenza and preparation method thereof | |
| CN112294911A (en) | Traditional Chinese medicine composition for treating cough with lung heat | |
| CN106138254A (en) | A kind of preparation method and applications of antiphlogistic bezoar buccal tablet | |
| WO2006007758A1 (en) | Traditional chinese medicine composition for treating acute and chronic nasosinusitis and preparation thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN102727627B (en) | Traditional Chinese medicine composition for treating heart failure and preparation method and application thereof | |
| CN111558008A (en) | A kind of weight loss and fat-reducing belly button patch, preparation method and application | |
| CN1939421A (en) | A Chinese medicinal composition with antibacterial and antiviral effects | |
| CN110464755A (en) | A kind of Chinese medicine composition tablet for treating acute pyelonephritis | |
| CN109663012A (en) | Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof | |
| CN117731709B (en) | Medicine for treating prostatitis and prostatic hyperplasia and preparation method and application thereof | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN101721437A (en) | Medicine composition used for treating chronic pharyngitis and preparation method thereof | |
| CN111467423B (en) | Honeysuckle flower and lotus root heat-clearing spray and preparation method thereof | |
| CN101176772B (en) | Pharmaceutical composition made of cattail pollen and safflower | |
| CN109453141B (en) | Preparation method of film agent for treating chronic pharyngitis | |
| CN108938749B (en) | Pharmaceutical composition and preparation method and application thereof | |
| TWI352596B (en) | ||
| CN117357614A (en) | Traditional Chinese medicine composition for improving children adenoid hypertrophy and application thereof, decoction, oral liquid and granules | |
| CN115813989A (en) | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |